Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

207.02B

Market cap207.02B

Price-Earnings ratio

26.24

Price-Earnings ratio26.24

Dividend yield

2.55%

Dividend yield2.55%

Average volume

3.27M

Average volume3.27M

High today

$380.44

High today$380.44

Low today

$370.44

Low today$370.44

Open price

$373.50

Open price$373.50

Volume

2.73M

Volume2.73M

52 Week high

$385.12

52 Week high$385.12

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

With a market cap of 207.02B, Amgen(AMGN) trades at $379.29. The stock has a price-to-earnings ratio of 26.24 and currently yields dividends of 2.5%.

During the trading session on 2026-02-19, Amgen(AMGN) shares reached a daily high of $380.44 and a low of $370.44. At a current price of $379.29, the stock is +2.4% higher than the low and still -0.3% under the high.

Trading volume for Amgen(AMGN) stock has reached 2.73M, versus its average volume of 3.27M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $385.12 and a low of $261.43.

AMGN News

TipRanks 19h

Amgen price target raised to $432 from $381 at Piper Sandler

Piper Sandler raised the firm’s price target on Amgen (AMGN) to $432 from $381 and keeps an Overweight rating on the shares after meeting with management. Key t...

Simply Wall St 4d

A Look At Amgen Valuation After Strong Q4 Results And New UPLIZNA Approval

Advertisement What Amgen’s latest quarter and new approval could mean for investors Amgen (AMGN) is back on investors’ radar after reporting fourth quarter an...

TipRanks 5d

Amgen files automatic mixed securities shelf

16:46 EST Amgen (AMGN) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Analyst ratings

50%

of 36 ratings

Buy

41.7%

Hold

50%

Sell

8.3%

More AMGN News

Simply Wall St 6d

UPLIZNA’s Expanded EU Use in Autoimmune Disease Could Be A Game Changer For Amgen

Amgen recently reported that the European Commission approved UPLIZNA (inebilizumab) as an add-on therapy for adults with generalized myasthenia gravis who are...

TipRanks 6d

Amgen downgraded to Hold from Buy at Freedom Capital

Freedom Capital downgraded Amgen (AMGN) to Hold from Buy with a price target of $375, up from $360. The firm views the company’s Q4 report as “strong.” However,...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Rockwell Automation

Cognex

WisdomTree Japan Hedged E…

Baker Hughes Company

SPDR EURO STOXX 50 ETF

TJX

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.